FDA approves J&J IMAAVY first WAIHA treatment for ages 12+
The FDA approves Johnson & Johnson’s IMAAVY as the first-ever treatment for warm autoimmune hemolytic anemia (WAIHA) in patients aged 12 and older.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.